Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
03 Février 2022 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing curative therapeutics
leveraging CRISPR-based technologies, today announced the
acquisition of Rewrite Therapeutics, Inc. (Rewrite), a private
biotechnology company focused on advancing novel DNA writing
technologies.
Rewrite has developed promising new tools for genome editing,
including DNA writing via CRISPR/Cas9-guided polymerases. Founded
by pioneering scientists Shakked Halperin, Ph.D., and Professor
David Schaffer, Ph.D., of the University of California, Berkeley
and backed by Civilization Ventures and Prefix Capital, Rewrite’s
DNA writing technology may enable a range of precise editing
strategies. These strategies include targeted corrections,
insertions, deletions, and the full range of single-nucleotide
changes, which could provide new ways to edit disease-causing genes
and broaden the therapeutic potential for genomic medicines.
Rewrite also has developed an approach that could improve the
efficiency of genome editing in non-dividing cell types, a key
challenge for some existing editing platforms. Rewrite’s technology
could potentially be delivered using Intellia’s lipid nanoparticle
(LNP) technology and adeno-associated virus (AAV) vectors.
“At Intellia, we have built the industry’s broadest and deepest
genome editing platform by staying at the forefront of new
techniques, while also extending the capabilities of CRISPR/Cas9
editing to make precisely targeted changes to DNA,” said Intellia
President and Chief Executive Officer John Leonard, M.D. “We could
not be more excited to add Rewrite’s additional capabilities to our
growing platform, offering us new possibilities and the potential
to target diseases beyond those currently being explored in our
pipeline.”
Dr. Halperin, Rewrite’s President and Chief Executive Officer
and the inventor of Rewrite’s gene editing platform, said:
"Since my initial discovery that CRISPR-guided polymerases could
help advance genome editing capabilities, I have focused my efforts
on developing a suite of genome editing tools that could one day be
used to create innovative and potentially curative treatments for
patients with life-threatening diseases. I am thrilled that these
inventions will now be leveraged by the industry leader, Intellia,
so that the full power and potential of genome editing can be
harnessed to benefit patients.”
As part of this transaction, Intellia will pay the Rewrite
shareholders $45 million in an upfront payment and an additional
$155 million in pre-specified research and regulatory approval
milestones through a mix of Intellia common stock and cash.
Additional financial details were not disclosed.
Goodwin Procter, Latham & Watkins and Finnegan acted as
Intellia’s legal counsel. Arnold & Porter Kaye Scholer and
Wilson, Sonsini, Goodrich & Rosati acted as Rewrite’s legal
counsel.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
leveraging CRISPR-based technologies. To fully realize the
transformative potential of CRISPR-based technologies, Intellia is
pursuing two primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding Intellia’s beliefs and expectations regarding:
its strategy, business plans and focus; its ability to quickly and
efficiently realize the scope and potential of its genome editing
technologies, including the technologies acquired in the Rewrite
acquisition; its ability to maintain, expand and maximize its
intellectual property portfolio, including intellectual property
acquired in the Rewrite acquisition, and pipeline, as well as
accelerate clinical validation for its platform; the therapeutic
value and development potential of CRISPR genome editing
technologies and therapies, including the technologies acquired in
the Rewrite acquisition; its ability to combine its CRISPR genome
editing platform and technologies with the platform and
technologies acquired in the Rewrite acquisition; and the expected
strategic benefits of the Rewrite acquisition or any current or
future collaborations.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks related to Intellia’s ability to protect and
maintain its intellectual property portfolio, including the
intellectual property acquired in the Rewrite acquisition; risks
related to Intellia’s relationship with third parties, including
its licensors and licensees; risks related to the ability of
Intellia’s licensors to protect and maintain their intellectual
property position; uncertainties related to the authorization,
initiation and conduct of studies and other development
requirements for the new company’s product candidates; the risk
that the research-stage technology acquired in the Rewrite
acquisition will not be successfully developed and commercialized;
and the risk that the results of preclinical studies or clinical
studies will not be predictive of future results in connection with
future studies. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Intellia’s most recent annual report on Form 10-K and quarterly
report on Form 10-Q filed with the SEC, as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission. Any forward-looking statements contained in this press
release represent Intellia’s views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Intellia explicitly disclaims any obligation to
update any forward-looking statements, except as required by
law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com Lina
LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Matt Crenson Ten Bridge
Communications+1-917-640-7930media@intelliatx.com
mcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024